| Phase I trial of MDXH210 (Fc@cRI @? HER-2/neu, bispecific antibody) incombination with G-CSF in patients with metastatic breast cancer. |
van Ojik, H.;Groenewegen, G.;Repp, R.;Valerius, T.;van Oers, A.;Westerdaal, N.A.C.;Deo, Y.;Blijham, G.H.;van de Winkel, J.G.J.; |
The Netherlands Journal of Medicine |
1996-05-01 |
查看 |
